EOLS (Evolus) Shareholder Yield % : -6.35% (As of Mar. 2026)


EOLS Evolus Inc EOLS
66 GF Score
Price $6.78
GF Value $13.62
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Evolus Shareholder Yield %?

Evolus EOLS +0.37% 66 Shareholder Yield % is -6.35% as of Mar. 2026. GuruFocus rates EOLS with a GF Score™ of 66/100 and a GF Value™ of $13.62 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 970 Drug Manufacturers companies, Evolus ranks worse than 79.79% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Evolus's Shareholder Yield % was -6.35%.


Evolus  (NAS:EOLS) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Evolus Shareholder Yield % Related Terms


Evolus Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Evolus's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolus Shareholder Yield % Chart

Evolus Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.13 -9.03 -4.14 -11.38 -4.73

Evolus Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.65 -2.67 -3.78 -4.73 -10.43

EOLS vs NIKA, EBS, ELTP: Shareholder Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolus Shareholder Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evolus's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Evolus's Shareholder Yield % falls into.


EOLS
66GF Score
Evolus Inc EOLS
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evolus Shareholder Yield % Calculation

Evolus's Shareholder Yield % for the quarter that ended in Mar. 2026 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+0.00 %+-10.43 %
=-10.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -6.35% mean?
Evolus (EOLS) has a Shareholder Yield % of -6.35% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Evolus and its competitors. According to the industry distribution chart, Evolus ranks #774 out of 970 companies in the Drug Manufacturers industry, placing it in the top 79.8%.
Is Evolus' Shareholder Yield % too high?
Evolus' current Shareholder Yield % is -6.35%. Based on the distribution chart, Evolus ranks #774 out of 970 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evolus has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' Shareholder Yield % compare to NIKA and EBS?
According to the Drug Manufacturers industry distribution chart, Evolus ranks #774 out of 970 companies for Shareholder Yield %. This places Evolus in the lower half of its industry. The industry median Shareholder Yield % is 0.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.34, based on 970 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Evolus and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolus's current Shareholder Yield % is -6.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (EOLS) is currently considered Possible Value Trap. The stock's GF Value™ is $13.62, compared to a current price of $6.78 — trading 50.3% below its estimated fair value. The current Shareholder Yield % is -6.35%. Evolus' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Evolus (EOLS), the current Shareholder Yield % is -6.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evolus (EOLS) Overvalued in 2026?

Based on GuruFocus' analysis, Evolus stock appears to be undervalued. The current stock price of $6.78 is trading 50.3% below its estimated GF Value™ of $13.62. GuruFocus considers Evolus to be Possible Value Trap.

Key valuation signals for EOLS:

  • Shareholder Yield %: -6.35%
  • GF Value™: $13.62 vs. price of $6.78 (50.3% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evolus Business Description

Other Exchanges EVL:Germany
Address 520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
66GF Score

Get the complete analysis for EOLS

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.78
Price
$13.62
GF Value